2015 Guidance on cancer immunotherapy development in early-phase clinical studies

Cancer Science

Volumn 106, Issue 12, 2015, Pages 1761-1771

  Arato, Teruyo ^a   Yamaguchi, Yoshiyuki ^a,o   Daimon, Takashi ^b   Heike, Yuji ^c   Ishii, Ken ^d   Kobiyama, Kouji ^d   Itho, Kyogo ^e   Kageyama, Shinichi ^f   Shiku, Hiroshi ^f   Miyahara, Yoshihiro ^f   Ikeda, Hiroaki ^f   Harada, Naozumi ^f   Muraoka, Daisuke ^f   Kawakami, Yutaka ^g   Nakayama, Eiichi ^h   Ozawa, Keiya ⁱ   Sato, Noriyuki ^j   Takeuchi, Masahiro ^k   Tani, Kenzaburo ^l   Tamada, Koji ^m   Ueda, Ryuzo ⁿ   Yamanaka, Takeharu ^p   Yamaue, Hiroki ^q   Yasukawa, Masaki ^r   Iguchi, Toyotaka ^s   Terashima, Takeshi ^s   Amakasu, Kohei ^s   Kitano, Shigehisa ^t   Nagata, Yasuhiro ^u   Noguchi, Masanori ^e   Asano, Takeo ^v   Asonuma, Motohiro ^w   Kakimi, Kazuhiro ^x   Takesako, Kazutoh ^y   Tanaka, Masanori ^z   Yamada, Akira ^e   Aoshi, Taiki ^aa   Kuroda, Etsushi ^v   Yamazaki, Naoya ^ab   Kuchiba, Aya ^t   Tanaka, Shiro ^ac   Michimae, Hirofumi ^k   Yamada, Tomomi ^v   Hanada, Kenichi ^ad   Okada, Hideho ^ae   Takebe, Naoko ^ad   Hirano, Naoto ^af   Okumura, Satoshi ^s   Shibatsuji, Masayoshi ^s   Sato, Daisaku ^ag   Yamaguchi, Teruhide ^ag   more..

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^e KURUME UNIVERSITY   (Japan)

^f MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

^j SAPPORO MEDICAL UNIVERSITY   (Japan)

^k KITASATO UNIVERSITY   (Japan)

^l KYUSHU UNIVERSITY   (Japan)

^m YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o KAWASAKI MEDICAL SCHOOL   (Japan)

^p YOKOHAMA CITY UNIVERSITY   (Japan)

^q WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^r EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^s PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^t NATIONAL CANCER CENTER   (Japan)

^u NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^v OSAKA UNIVERSITY   (Japan)

^w JUNTENDO UNIVERSITY   (Japan)

^x UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^y Japan Human Sciences Foundation   (Japan)

^z Japan Res Assoc Immunotherapeutics   (Japan)

^aa OSAKA UNIVERSITY   (Japan)

^ab NATIONAL CANCER CENTER HOSPITAL   (Japan)

^ac KYOTO UNIVERSITY   (Japan)

^ad NATIONAL CANCER INSTITUTE   (United States)

^ae UNIVERSITY OF CALIFORNIA   (United States)

^af PRINCESS MARGARET HOSPITAL   (Canada)

^ag National Institutes of Health ^*

more..

Author keywords

Cancer vaccines; Cell therapy; Clinical trial; Immunotherapy; Monoclonal antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; IMMUNE CHECKPOINT INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CLINICAL FEATURE; COLITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EFFECTOR CELL; ENDOCRINE DISEASE; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL HISTORY; MEDICAL LITERATURE; NEOPLASM; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SKIN DISEASE; STUDY DESIGN; TISSUE INJURY; TREATMENT RESPONSE; VACCINATION REACTION; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PROCEDURES; STANDARDS;

CANCER VACCINES; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; RESEARCH DESIGN;

EID: 84956701460     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12819     Document Type: Article

References (56)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
2. Maus MV, Fraietta JA, Levine BL et al. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014; 32: 189-225.
3. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013; 39: 61-73.
4. Coulie PG, van den Eynde BJ, van der Bruggen P et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14: 135-46.
5. Amos SM, Duong CPM, Westwood JA et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118: 499-509.
6. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-7.
7. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003; 21: 2415-32.
8. Bachmann MF, Gary T, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10: 787-96.
9. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19: 1597-608.
10. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
11. Beer TM, Schellhammer PF, Corman JM et al. Quality of life after Sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology 2013; 82: 410-5.
12. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014; 257(1): 56-71.
13. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622-32.
14. Fisher JP, Heuijerjans J, Yan M et al. γδ T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology 2014; 3: e27572.
15. Wada I, Matsushita H, Noji S et al. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med 2014; 3: 362-75.
16. Cheng M, Chen Y, Weihua X et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013; 10: 230-52.
17. Fujii S, Shimizu K, Okamoto Y et al. NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol 2013; 4: 409.
18. Kunert A, Straetemans T, Govers C et al. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol 2013; 4: 363.
19. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123: 2625-35.
20. Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra25.
21. Louis CU, Savoldo B, Brenner MK et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118: 6050-6.
22. Buccheri S, Guggino G, Caccamo N et al. Effficacy and safety of γδ cell-based immunotherapy: a meta-analysis. J Biol Regul Homeost Agents 2014; 28: 81-90.
23. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
24. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Eng J Med 2012; 366: 2455-65.
25. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-75.
26. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-44.
27. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010; 363: 711-23.
28. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Eng J Med 2011; 364: 2517-26.
29. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
30. Janetzki S, Britten CM, Kalos M et al. "MIATA"-minimal information about T cell assays. Immunity 2009; 31: 527-8.
31. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18: 1254-61.
32. hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008; 105: 14987-92.
33. Bindea G, Mlecnik B, Galon J et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39: 782-95.
34. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
35. Kitano S, Postow MA, Ziegler CG et al. Computational algorithm driven evaluation of monocytic myeloid derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res 2014; 2: 812-21.
36. Solito S, Marigo I, Bronte V et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014; 1319: 47-65.
37. + T cells in a patient with epithelial cancer. Science 2014; 344: 641-5.
38. Robbins PF, Lu YC, El-Gamil M et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19: 747-52.
39. Castle JC, Kreiter S, Diekmann J et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72: 1081-91.
40. Matsushita H, Vesely MD, Koboldt DC et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482: 400-4.
41. Britten CM, Singh-Jasuja H, Flamion B et al. The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol 2013; 31: 880-2.
42. Yamada A, Sasada T, Noguchi M et al. Next-generation peptide vaccines for advanced cancer. Cancer Sci 2013; 104: 15-21.
43. Simon R. Clinical trial designs for therapeutic vaccine studies. In: Morse MA, Timothy M, Clay TM, Lyerly HK, eds. Handbook of Cancer Vaccines. New York: Human Press, 2004; 519-25.
44. Simon R. Clinical trial designs for therapeutic cancer vaccines. In: Khleif SN, eds. Tumor Immunology and Cancer Vaccines. Dordrecht, the Netherlands: Kluwer Academic Publishers, 2005; 339-50.
45. Simon RM, Steinberg SM, Hamilton M et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001; 19: 1848-54.
46. Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian Adaptive Methods for Clinical Trials. Boca Raton, FL: CRC Press, 2011.
47. Yin G. Clinical Trial Design: Bayesian and Frequentist Adaptive Methods. New York, NY: John Wiley & Sons Inc, 2012.
48. Yin G, Zheng S, Xu J. Two-stage dose finding for cytostatic agents in phase I oncology trials. Stat Med 2012; 32: 644-60.
49. Thall PF, Nguyen HQ, Braun TM, Qazilbash MH. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose. Biometrics 2013; 69: 673-82.
50. Ji Y, Wang SJ. Modified toxicity probability interval design: a safer and more reliable method than the 3+3 design for practical phase I trials. J Clin Oncol 2013; 31: 1785-91.
51. Messer K, Natarajan L, Ball ED et al. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials. Stat Med 2010; 29: 712-20.
52. Hunsberger S, Rubinstein LV, Dancey J, Korn EL. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med 2005; 24: 2171-81.
53. Hoering A, LeBlanc M, Crowley J. Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents. Clin Cancer Res 2011; 17: 640-6.
54. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-20.
55. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94.
56. Rubinstein L, Crowley J, Ivy P et al. Randomized phase II designs. Clin Cancer Res 2009; 15: 1883-90.